Skip to main content
Erschienen in: Clinical & Experimental Metastasis 5/2014

01.06.2014 | Research Paper

Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression

verfasst von: Rehan Khan, Nidhi Gupta, Raman Kumar, Manoj Sharma, Lalit Kumar, Alpana Sharma

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) represents a B cell malignancy, characterized by a monoclonal proliferation of malignant plasma cells. Interactions between tumor cells and extracellular matrix (ECM) are of importance for tumor invasion and metastasis. Protein levels of urokinase plasminogen activator (uPA) and fibulin 1, nidogen and laminin in plasma and serum respectively and mRNA levels of these molecules in peripheral blood mononuclear cells were determined in 80 subjects by using ELISA and quantitative PCR and data was analyzed with severity of disease. Pearson correlation was determined to observe interrelationship between different molecules. A statistical significant increase for ECM proteins (laminin, nidogen and fibulin 1) and uPA at circulatory level as well as at mRNA level was observed compared to healthy controls. The levels of these molecules in serum might be utilized as a marker of active disease. Significant positive correlation of all ECM proteins with uPA was found and data also correlates with severity of disease. Strong association found between ECM proteins and uPA in this study supports that there might be interplay between these molecules which can be targeted. This study on these molecules may help to gain insight into processes of growth, spread, and clinical behavior of MM.
Literatur
1.
Zurück zum Zitat Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2:233–241PubMed Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2:233–241PubMed
2.
Zurück zum Zitat Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G (2006) Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 21:218–222PubMed Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G (2006) Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 21:218–222PubMed
4.
Zurück zum Zitat Ashkenas J, Muschler J, Bissell M (1996) The extracellular matrix in epithelial biology, shared molecules and common themes in distinct phyla. Dev Biol 17:433–444CrossRef Ashkenas J, Muschler J, Bissell M (1996) The extracellular matrix in epithelial biology, shared molecules and common themes in distinct phyla. Dev Biol 17:433–444CrossRef
5.
Zurück zum Zitat Dziadek M (1995) Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Experientia 51:901–913PubMedCrossRef Dziadek M (1995) Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Experientia 51:901–913PubMedCrossRef
6.
Zurück zum Zitat Klominek J, Robert KH, Sundqvist KG (1993) Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen and an autocrine motility factor-like substance. Cancer Res 53:4376–4382PubMed Klominek J, Robert KH, Sundqvist KG (1993) Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen and an autocrine motility factor-like substance. Cancer Res 53:4376–4382PubMed
7.
Zurück zum Zitat Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C (2004) The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 117:1495–1502PubMedCrossRef Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C (2004) The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 117:1495–1502PubMedCrossRef
9.
Zurück zum Zitat Spessotto P, Yin Z, Magro G, Deutzmann R, Chiu A, Colombatti A, Perris R (2001) Laminin isoforms 8 and 10 are primary components of the subendothelial basement membrane promoting interaction with neoplastic lymphocytes. Cancer Res 61:339–347PubMed Spessotto P, Yin Z, Magro G, Deutzmann R, Chiu A, Colombatti A, Perris R (2001) Laminin isoforms 8 and 10 are primary components of the subendothelial basement membrane promoting interaction with neoplastic lymphocytes. Cancer Res 61:339–347PubMed
10.
Zurück zum Zitat Ramos DM, Cheng YF, Kramer RH (1991) Role of laminin-binding integrin in the invasion of basement membrane matrices by fibrosarcoma cells. Invasion Metastasis 11:125–138PubMed Ramos DM, Cheng YF, Kramer RH (1991) Role of laminin-binding integrin in the invasion of basement membrane matrices by fibrosarcoma cells. Invasion Metastasis 11:125–138PubMed
11.
Zurück zum Zitat Timpl R, Brown J (1996) Supramolecular assembly of basement membranes. Bioassays 18:123–132CrossRef Timpl R, Brown J (1996) Supramolecular assembly of basement membranes. Bioassays 18:123–132CrossRef
12.
Zurück zum Zitat Yi XY, Wayner E, Kim Y, Fish A (1998) Adhesion of cultured human kidney mesangial cells to native entactin: role of integrin receptors. Cell Adhes Commun 5:237–248PubMedCrossRef Yi XY, Wayner E, Kim Y, Fish A (1998) Adhesion of cultured human kidney mesangial cells to native entactin: role of integrin receptors. Cell Adhes Commun 5:237–248PubMedCrossRef
13.
Zurück zum Zitat Miosge N, Sasaki T, Timpl R (2002) Evidence of nidogen-2 compensation for nidogen-1 deficiency in transgenic mice. Matrix Biol 21:611–621PubMedCrossRef Miosge N, Sasaki T, Timpl R (2002) Evidence of nidogen-2 compensation for nidogen-1 deficiency in transgenic mice. Matrix Biol 21:611–621PubMedCrossRef
14.
Zurück zum Zitat Rouleau C, Roy A, St Martin T, Dufault, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher BA (2006) Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Mol Cancer Ther 5:219–229PubMedCrossRef Rouleau C, Roy A, St Martin T, Dufault, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher BA (2006) Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Mol Cancer Ther 5:219–229PubMedCrossRef
15.
Zurück zum Zitat Blasi F (1997) upa, upar, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18:415–417PubMedCrossRef Blasi F (1997) upa, upar, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18:415–417PubMedCrossRef
16.
Zurück zum Zitat Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM (1995) Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270:603–611PubMedCrossRef Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM (1995) Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270:603–611PubMedCrossRef
17.
Zurück zum Zitat Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380–32388PubMed Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380–32388PubMed
18.
Zurück zum Zitat Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G (2003) Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br J Haematol 120:953–959PubMedCrossRef Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G (2003) Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br J Haematol 120:953–959PubMedCrossRef
19.
Zurück zum Zitat Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14:297–307PubMed Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14:297–307PubMed
20.
Zurück zum Zitat Hannocks MJ, Oliver L, Gabrilove JL, Wilson EL (1992) Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood 79:1178–1184PubMed Hannocks MJ, Oliver L, Gabrilove JL, Wilson EL (1992) Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood 79:1178–1184PubMed
21.
Zurück zum Zitat Gallagher WM, Currid CA, Whelan LC (2005) Fibulins and cancer: friend or foe? Trends Mol Med 11:336–340PubMedCrossRef Gallagher WM, Currid CA, Whelan LC (2005) Fibulins and cancer: friend or foe? Trends Mol Med 11:336–340PubMedCrossRef
22.
Zurück zum Zitat Greene LM, Twal WO, Duffy MJ, McDermott EW, Hill AD, O’Higgins NJ, McCann AH, Dervan PA, Argraves WS, Gallagher WM (2003) Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 88:871–878PubMedCentralPubMedCrossRef Greene LM, Twal WO, Duffy MJ, McDermott EW, Hill AD, O’Higgins NJ, McCann AH, Dervan PA, Argraves WS, Gallagher WM (2003) Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 88:871–878PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Hazlehurst LA, Dalton WS (2001) Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20:43–50PubMedCrossRef Hazlehurst LA, Dalton WS (2001) Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20:43–50PubMedCrossRef
24.
Zurück zum Zitat Khan R, Sharma M, Kumar L, Husain SA, Sharma A (2013) Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma. Ann Hematol 92:101–109PubMedCrossRef Khan R, Sharma M, Kumar L, Husain SA, Sharma A (2013) Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma. Ann Hematol 92:101–109PubMedCrossRef
25.
Zurück zum Zitat Neri P, Bahlis NJ (2012) Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets 12:776–796PubMedCrossRef Neri P, Bahlis NJ (2012) Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets 12:776–796PubMedCrossRef
26.
Zurück zum Zitat Witzig T, Dhodapkar M, Kyle R, Greipp P (1993) Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72:108PubMedCrossRef Witzig T, Dhodapkar M, Kyle R, Greipp P (1993) Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72:108PubMedCrossRef
27.
Zurück zum Zitat Kibler C, Schermutzki F, Waller HD, Timpl R, Müller CA, Klein G (1998) Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 5:307–323PubMedCrossRef Kibler C, Schermutzki F, Waller HD, Timpl R, Müller CA, Klein G (1998) Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 5:307–323PubMedCrossRef
28.
Zurück zum Zitat Faid L, Van Riet I, De Waele M, Facon T, Schots R, Lacor P, Van Camp B (1996) Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur J Haematol 57:349–358PubMedCrossRef Faid L, Van Riet I, De Waele M, Facon T, Schots R, Lacor P, Van Camp B (1996) Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur J Haematol 57:349–358PubMedCrossRef
29.
Zurück zum Zitat Broek IV, Vanderkerken K, De Greef C, Asosingh K, Straetmans N, Van Camp B, Van Riet I (2001) Laminin-1-induced migration of multiple myeloma cells involves the highaffinity 67 kD laminin receptor. Br J Cancer 85:1387–1395CrossRef Broek IV, Vanderkerken K, De Greef C, Asosingh K, Straetmans N, Van Camp B, Van Riet I (2001) Laminin-1-induced migration of multiple myeloma cells involves the highaffinity 67 kD laminin receptor. Br J Cancer 85:1387–1395CrossRef
30.
Zurück zum Zitat Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J (2009) Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem 57:239–247PubMedCentralPubMedCrossRef Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J (2009) Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem 57:239–247PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Mutlu P, Ural AU, Gündüz U (2012) Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. Biomed Pharmacother 66:228–231PubMedCrossRef Mutlu P, Ural AU, Gündüz U (2012) Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. Biomed Pharmacother 66:228–231PubMedCrossRef
32.
Zurück zum Zitat Daci E, Everts V, Torrekens S, Van Herck E, Tigchelaar-Gutterr W, Bouillon R, Carmeliet G (2003) Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 18:1167–1176PubMedCrossRef Daci E, Everts V, Torrekens S, Van Herck E, Tigchelaar-Gutterr W, Bouillon R, Carmeliet G (2003) Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 18:1167–1176PubMedCrossRef
33.
Zurück zum Zitat Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932–943PubMedCrossRef Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932–943PubMedCrossRef
34.
Zurück zum Zitat Monvoisin A, Neaud V, De Ledinghen V, Dubuisson L, Balabaud C, Bioulac-Sage P, Desmouliere A, Rosenbaum J (1999) Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 30:511–518PubMedCrossRef Monvoisin A, Neaud V, De Ledinghen V, Dubuisson L, Balabaud C, Bioulac-Sage P, Desmouliere A, Rosenbaum J (1999) Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 30:511–518PubMedCrossRef
35.
Zurück zum Zitat Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122–136PubMedCrossRef Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122–136PubMedCrossRef
36.
Zurück zum Zitat Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, Waage A, Sundan A, Borset M (2000) Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 109:815–822PubMedCrossRef Hjertner O, Qvigstad G, Hjorth-Hansen H, Seidel C, Woodliff J, Epstein J, Waage A, Sundan A, Borset M (2000) Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 109:815–822PubMedCrossRef
37.
Zurück zum Zitat Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O (2007) Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 138:446–458PubMedCrossRef Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O (2007) Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 138:446–458PubMedCrossRef
38.
Zurück zum Zitat Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K (2004) Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 33:111–119PubMedCrossRef Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K (2004) Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 33:111–119PubMedCrossRef
39.
Zurück zum Zitat Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11:31–44PubMedCrossRef Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11:31–44PubMedCrossRef
40.
Zurück zum Zitat Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafà R, Manfredini S, Farinati F, Sasaki T, Lanza G, Negrini M (2007) Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer 6:17–25PubMedCentralPubMedCrossRef Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafà R, Manfredini S, Farinati F, Sasaki T, Lanza G, Negrini M (2007) Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer 6:17–25PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Schmoeckel C, Stolz W, Sakai LY, Burgeson RE, Timpl R, Krieg T (1989) Structure of basement membranes in malignant melanoma and nevocytic nevi. J Invest Dermatol 92:663–668PubMedCrossRef Schmoeckel C, Stolz W, Sakai LY, Burgeson RE, Timpl R, Krieg T (1989) Structure of basement membranes in malignant melanoma and nevocytic nevi. J Invest Dermatol 92:663–668PubMedCrossRef
42.
Zurück zum Zitat Cheng Z, Huang XH, Wang Q, Chen JS, Zhang LJ, Chen XL (2012) Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma. J Surg Oncol 105:71–80PubMedCrossRef Cheng Z, Huang XH, Wang Q, Chen JS, Zhang LJ, Chen XL (2012) Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma. J Surg Oncol 105:71–80PubMedCrossRef
43.
Zurück zum Zitat Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62:4722–4729PubMed Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62:4722–4729PubMed
44.
Zurück zum Zitat Creighton C, Hanash S (2003) Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. In Silico Biol 3:301–311PubMed Creighton C, Hanash S (2003) Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. In Silico Biol 3:301–311PubMed
45.
Zurück zum Zitat Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B (2009) Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS 13:345–354PubMedCrossRef Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B (2009) Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS 13:345–354PubMedCrossRef
46.
Zurück zum Zitat Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H, Pujol P (2002) Estrogen induction and overexpression of fibulin 1C mRNA in ovarian cancer cells. Oncogene 21:1097–1107PubMedCrossRef Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H, Pujol P (2002) Estrogen induction and overexpression of fibulin 1C mRNA in ovarian cancer cells. Oncogene 21:1097–1107PubMedCrossRef
47.
Zurück zum Zitat Talts JF, Weller A, Timpl R, Ekblom M, Ekblom P (1995) Regulation of mesenchymal extracellular matrix protein synthesis by transforming growth factor-b and glucocorticoids in tumor stroma. J Cell Sci 108:2153–2162PubMed Talts JF, Weller A, Timpl R, Ekblom M, Ekblom P (1995) Regulation of mesenchymal extracellular matrix protein synthesis by transforming growth factor-b and glucocorticoids in tumor stroma. J Cell Sci 108:2153–2162PubMed
48.
Zurück zum Zitat Xie L, Palmsten K, MacDonald B, Kieran MW, Potenta S, Vong S, Kalluri R (2008) Inhibitors and suppress tumor growth basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis. Exp Biol Med 233:155–162CrossRef Xie L, Palmsten K, MacDonald B, Kieran MW, Potenta S, Vong S, Kalluri R (2008) Inhibitors and suppress tumor growth basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis. Exp Biol Med 233:155–162CrossRef
49.
Zurück zum Zitat Twal WO, Czirok A, Hedegus B, Knaak C, Chintalapudi MR, Okagawa H, Sugi Y, Argraves WS (2001) Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 114:4587–4598PubMed Twal WO, Czirok A, Hedegus B, Knaak C, Chintalapudi MR, Okagawa H, Sugi Y, Argraves WS (2001) Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 114:4587–4598PubMed
50.
Zurück zum Zitat Qing J, Maher VM, Tran H, Argraves WS, Dunstan RW, McCormick JJ (1997) Suppression of anchorage-independent growth and Matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 15:2159–2168PubMedCrossRef Qing J, Maher VM, Tran H, Argraves WS, Dunstan RW, McCormick JJ (1997) Suppression of anchorage-independent growth and Matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 15:2159–2168PubMedCrossRef
51.
Zurück zum Zitat Kubista B, Klinglmueller F, Bilban M, Pfeiffer M, Lass R, Giurea A, Funovics PT, Toma C, Dominkus M, Kotz R, Thalhammer T, Trieb K, Zettl T, Singer CF (2011) Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma. Int Orthop 35:401–411PubMedCentralPubMedCrossRef Kubista B, Klinglmueller F, Bilban M, Pfeiffer M, Lass R, Giurea A, Funovics PT, Toma C, Dominkus M, Kotz R, Thalhammer T, Trieb K, Zettl T, Singer CF (2011) Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma. Int Orthop 35:401–411PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S, Nakao A (2011) Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 50:571–579PubMedCrossRef Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S, Nakao A (2011) Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog 50:571–579PubMedCrossRef
Metadaten
Titel
Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression
verfasst von
Rehan Khan
Nidhi Gupta
Raman Kumar
Manoj Sharma
Lalit Kumar
Alpana Sharma
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 5/2014
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9652-7

Weitere Artikel der Ausgabe 5/2014

Clinical & Experimental Metastasis 5/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.